Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. Most studies examining phentermine monotherapy have lim-ited treatment duration to less than 12 weeks (20), aligning with a package insert that recommends that the medication be used as “a short-term adjunct (a few weeks)” to lifestyle-based programs (21). Concerns about longer-term phentermine use include increased risk.

  2. This review provides an overview of the history, mechanism of action, and expected treatment effects of the anti-obesity medication (AOM), phentermine. It also includes a summary of recent research and practical guidance for prescribing clinicians.

  3. Objective: To formulate clinical practice guidelines for the pharmacological management of obesity. Participants: An Endocrine Society-appointed Task Force of experts, a methodologist, and a med-ical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society.

  4. Providing universal guidance regarding phentermine treatment for obesity is challenging because of the lack of long-term, prospective, randomized, placebo-controlled, health outcomes data. Such data is unlikely forthcoming any time soon.

  5. Multivariable linear models were used to compare percent weight loss across categories at 6, 12, and 24 months, and Cox proportional hazards models were used to compare risk of composite CVD or death, up to 3 years after starting phentermine.

  6. 20 sie 2024 · Current guidelines recommend that individuals who have attempted lifestyle improvements and continue to have a body mass index (BMI) of ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with an obesity-related comorbidity are eligible for weight loss medication treatment.

  7. All identified studies with short-term treatment used phentermine doses between 15 and 37.5 mg daily vs placebo for 12 weeks, except 2 studies 120, 122 that used phentermine 15 mg daily for 26–28 weeks.

  1. Ludzie szukają również